Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

  • Landos Biopharma Inc LABP and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and select Asian markets.
  • Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and Eosinophilic Esophagitis (EoE).
  • NX-13 is a novel, oral, gut-restricted NLRX1 targeting compound in development to treat UC and CD.
  • Under the terms of the collaboration, Landos will receive an upfront cash payment of $18 million and is eligible to receive milestone payments of up to $200 million.
  • Landos is also eligible to receive tiered low double-digit royalties.
  • LianBio will fund development and commercialization expenses in the collaboration territory, and Landos will continue to fund all development and commercialization expenses in all other geographies.
  • Landos reported a Q1 loss of $(9.8) million, higher than the $5.8 million reported a year ago.
  • The company held cash and equivalents of $106.4 million.
  • Price Action: LABP shares are up 2.58% at $11.95 in the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!